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Haemophilus ducreyi, the etiologic agent of chancroid, has an obligate requirement for heme. Heme is
acquired by H. ducreyi from its human host via TonB-dependent transporters expressed at its bacterial surface.
Of 3 TonB-dependent transporters encoded in the genome of H. ducreyi, only the hemoglobin receptor, HgbA,
is required to establish infection during the early stages of the experimental human model of chancroid. Active
immunization with a native preparation of HgbA (nHgbA) confers complete protection in the experimental
swine model of chancroid, using either Freund’s or monophosphoryl lipid A as adjuvants. To determine if
transfer of anti-nHgbA serum is sufficient to confer protection, a passive immunization experiment using
pooled nHgbA antiserum was conducted in the experimental swine model of chancroid. Pigs receiving this
pooled nHgbA antiserum were protected from a homologous, but not a heterologous, challenge. Passively
transferred polyclonal antibodies elicited to nHgbA bound the surface of H. ducreyi and partially blocked
hemoglobin binding by nHgbA, but were not bactericidal. Taken together, these data suggest that the humoral
immune response to the HgbA vaccine is protective against an H. ducreyi infection, possibly by preventing
acquisition of the essential nutrient heme.
The sexually transmitted genital ulcer disease (GUD) chan-
croid is caused by the Gram-negative bacterium Haemophilus
ducreyi (reviewed in references 9, 22, and 44). Although chan-
croid is currently considered rare in the United States (http:
//www.cdc.gov/std/stats08/other.htm), outbreaks of H. ducreyi
infection occurred in large American cities throughout the
1980s and 1990s (10, 25). During these times, chancroid was
endemic in sub-Saharan Africa, Asia, and the Caribbean (6,
44). It is difficult to assess the current epidemiology of chan-
croid because of syndromic management of GUDs and a lack
of reporting and diagnostic tools. Some publications regard-
ing the epidemiology of GUDs have described declining
numbers of chancroid cases worldwide (8, 29, 40), while
others have shown that H. ducreyi infections are still found
in pockets throughout the world (2, 5, 15, 31). H. ducreyi has
recently been shown to be the cause of lower limb cutaneous
ulcers in patients from the South Pacific (24, 30, 46). Chan-
croid is also an important cofactor in the heterosexual trans-
mission of the human immunodeficiency virus (HIV) (18,
32) and may have been particularly critical early in the HIV
epidemic (38).
H. ducreyi is an obligate human pathogen. Unable to syn-
thesize heme, H. ducreyi is thought to acquire this essential
compound from its host by binding hemoglobin (Hb) or free
heme using the TonB-dependent transporters (TBDTs)
HgbA and TdhA, respectively (11, 21, 27, 41). Only 3 TBDTs
are expressed by H. ducreyi: HgbA, an Hb receptor; TdhA, a
heme receptor; TdX, which has not been assigned a function
and is not expressed by all H. ducreyi strains (19). An isogenic
hgbA mutant of prototypical strain 35000HP is avirulent in the
human and rabbit experimental models of chancroid (3, 39),
proving that HgbA is a virulence factor for H. ducreyi. Con-
versely, a double tdhA/tdX mutant was fully virulent in the
human experimental model (19), which suggests the following
conclusions: (i) TdX and TdhA are not necessary for virulence
in early steps of H. ducreyi infection in the experimental human
model of chancroid; (ii) Hb is the most important source of
heme for H. ducreyi; (iii) HgbA is the most important TBDT
for acquisition of heme/iron by H. ducreyi.
By homology to other TBDTs, HgbA is thought to assume a
pore-like structure in the outer membrane of H. ducreyi, with
22 -strands, 11 putative surface-exposed loops, and a plug
region present in the periplasm (B. Temple, unpublished data)
(26). Using antisera from swine immunized with HgbA, our
laboratory showed that loops 4, 5, and 7 of HgbA are immu-
nogenic and that loop 4- and loop 5-specific antisera block Hb
binding to HgbA (26). By generating single-loop deletion mu-
tants of hgbA, we demonstrated that only deletion of loops 5
and 7 of HgbA substantially reduced Hb binding by HgbA.
However, deletion of any loop of the HgbA protein prevented
the use of Hb as a source of heme/iron by H. ducreyi (26).
Taken together, these data indicate that a central domain of
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the primary amino acid sequence of HgbA is important for
binding Hb by H. ducreyi.
Previous studies have shown that active immunization with a
native preparation of HgbA purified from H. ducreyi prototyp-
ical class I strain 35000HP (nHgbAI) protects against a homol-
ogous challenge in the experimental swine model of chancroid
(1, 13). Protection was observed when using either Freund’s
adjuvant or an adjuvant approved for use in humans, mono-
phosphoryl lipid A (MPL). Anti-nHgbAI antisera from both
vaccine trials bound HgbA at the surface of H. ducreyi and
partially blocked binding of Hb to nHgbAI. These in vitro
correlates of protection suggest that the humoral immune re-
sponse elicited to the HgbA vaccine may be protective. To
obtain evidence that antisera developed to the HgbA vaccine
may protect against an infectious challenge, we performed
classic passive immunization studies with antisera elicited
against nHgbAI in the experimental swine model of chancroid.
MATERIALS AND METHODS
Bacterial strains and culture conditions. H. ducreyi strain 35000HP is the
human-passaged variant (4) of wild-type isolate 35000 (14) and the prototypical
strain for H. ducreyi class I strains (48). Strain FX547 is an isogenic hgbA deletion
mutant of strain 35000HP (26), and FX548, an isogenic 35000HP strain in which
the hgbA gene was replaced with hgbA of strain DMC111, a class II H. ducreyi
strain (13). In this report, H. ducreyi strains 35000HP, FX547, and FX548 are
designated 35000HPhgbAI, 35000HPhgbA, and 35000HPhgbAII, respectively.
Other H. ducreyi strains used in this report include the 35000HP isogenic dsrA
mutant FX517 (12) and the isogenic momp (43) and ompA2 mutants (20), as well
as the gmhA mutant, termed 35000.252 (7).
H. ducreyi strains were routinely grown on chocolate agar plates (CAPs)
containing gonococcal (GC) medium base (Difco, Detroit, MI) and 1% bovine
Hb (Becton Dickinson, Sparks, MD) supplemented with 5% FetalPlex (Gemini
Bio-Products, West Sacramento, CA) and 1% GGC (0.1% glucose, 0.001%
glutamine, 0.026% cysteine) at 34.5°C in 5% CO2. For the purpose of nHgbAI
purification and whole-cell binding enzyme-linked immunosorbent assays
(ELISAs), H. ducreyi strains were cultured in low-heme GC broth (GCB; 1% GGC,
5% FetalPlex, and no addition of heme [1]).
Animals. A total of eight Yorkshire Cross (York) pigs (four pigs in each of two
separate passive immunization experiments) were obtained at 3 weeks of age and
housed at ambient temperature (20 to 25°C) in individual pens at the North
Carolina State University (NCSU) School of Veterinary Medicine. Animals were
given water and antibiotic-free high-protein feed ad libitum beginning 3 weeks
prior to the start of and throughout the study. During inoculation and biopsy
procedures, pigs were sedated with 2 mg of ketamine-HCl (Fort Dodge Labs,
Fort Dodge, IA) and 2 mg of xylazine (Miles Laboratories, Shawnee Mission,
KS) per kg of body weight, injected intramuscularly. At the time of biopsy, pigs
generally weighed between 15 and 25 kg. The Institutional Animal Care and Use
Committees (IACUC) at NCSU approved the methods and use of animals for
these experiments.
Preparation and passive immunization of the anti-nHgbAI polyclonal swine
antisera. A native preparation of the HgbA protein from class I H. ducreyi strain
35000HP (nHgbAI) was prepared as previously described from 12 liters of strain
35000HP grown in low-heme GCB (1). To ensure homogeneity of the nHgbAI
preparation used for active immunization, the preparation was monitored by
SDS-PAGE followed by Coomassie and silver staining (45), as well as Western
blotting with monoclonal antibody 2C7 to assess for the presence of the major
outer membrane proteins MOMP and OmpA2 (37). Based on these assays, the
nHgbAI protein preparation was over 95% pure, with very little contamination
with lipooligosaccharide (LOS) or MOMP/OmpA2 proteins (data not shown).
To generate the nHgbAI antisera, nHgbAI protein was sent to Covance (Cus-
tom Immunology Services, Denver, PA) for immunization of four York pigs.
Since all published pig studies, including the passive challenge described herein,
were done at NCSU, it is likely that the pigs used to develop anti-nHgbAI at
Covance came from a family line unrelated to the animals used for passive
immunization. This may explain the cross-reactivity seen in the antisera from
these animals (see Fig. 3 and 4 below). At Covance, each pig received three
immunizations of 250 g of nHgbAI in complete (first immunization) and in-
complete (second and third immunizations) Freund’s adjuvant (Sigma-Aldrich,
St. Louis, MO) at 3-week intervals, exactly as previously described (1). Three
weeks after the last immunization, animals were exsanguinated, and serum was
extracted from blood, aliquoted, and frozen at 20°C before being sent to our
laboratory.
Two days prior to infusion, 50 ml of antiserum from each of the 4 nHgbAI-
immunized pigs was pooled into one preparation, filter sterilized, and divided
into 50-ml aliquots. A pool of normal pig serum (NPS) was prepared in the same
manner from sera obtained from three pigs from the NCSU Veterinary School
which had previously been used for purposes other than infection (surgery) and
were already scheduled for euthanasia. The aliquots were kept at 4°C until the
day of the infusion. On the day of passive immunization, animals were sedated as
described above. Fifty milliliters of blood was removed from each animal, and 50
ml of pooled nHgbAI antiserum or NPS was passively administered through the
brachiocephalic vein at the trunk by using a 60-ml syringe and a 1.50-in. 20-gauge
needle. Depending on the size of the pigs (between 15 and 25 kg), and
assuming a mean blood volume of 62.5 ml/kg (http://www.iacuc.ucsf.edu/Proc
/awSwineNorm.asp), the infused nHgbAI antisera accounted for 3 to 5% of the
blood volume of passively immunized animals. Preparations of anti-nHgbAI and
NPS were tested for the presence of endotoxin by using the end point chromo-
genic Limulus amebocyte assay from Lonza (catalog number 50-647U) following
the manufacturer’s instructions. All infused sera had endotoxin concentrations
below 1 endotoxin unit/ml (data not shown).
For experiments described here, sera generated in the previously published
active immunization HgbA vaccine trial with Freund’s adjuvant (1) were used as
positive controls in many assays (see Fig. 3 to 6 below). These sera were purified
from blood taken 3 weeks after the third immunization (prior to infection) from
nHgbAI/Freund’s-immunized animals (pigs number 6, 7, and 8; serum from pig
5 was unavailable).
ELISA studies. A direct ELISA (see Fig. 2, below) was used to evaluate the
reactivities of individual and pooled nHgbAI antisera to purified nHgbA, using
changes to the protocol previously described (1, 13). An indirect ELISA, based
on a kit from Bethyl Laboratories (catalog number E100-104; Montgomery, TX),
was used to measure the quantity of nHgbAI-specific IgGs in the passively
transferred antisera and the antisera from passively immunized animals. In this
assay, wells coated either with nHgbAI or goat anti-pig antibodies (Abs) from the
Bethyl kit were incubated with dilutions of the passively transferred antisera or
antisera from animals passively immunized with anti-nHgbAI. Pig sera with
known amounts of IgG were added to wells with anti-pig IgG to generate a
standard curve. Wells were thereafter washed, incubated with anti-pig IgG con-
jugated to horseradish peroxidase (HRP), and developed as previously described
(1, 13). The amount of nHgbAI-specific IgG in the pig antisera was determined
by comparing the optical density obtained with the antisera to that of the
standard curve (49). A whole-cell binding ELISA was also used to measure the
reactivity of the antisera to HgbA expressed on the surface of intact H. ducreyi
strains 35000HPhgbAI, 35000HPhgbAII, 35000HPhgbA, and DMC111. A vac-
uum manifold was used to remove unbound components of the antisera, and Ab
reactivity was determined using HRP-conjugated anti-pig IgGs, as previously
described (1, 13).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blotting. Total cellular proteins (from 2.5  107 CFU of H. ducreyi
strains grown in low-heme GCB) were separated on a 4-to-12% gradient dena-
turing/reducing bis-Tris NuPAGE gel (Invitrogen, Carlsbad, CA) (150 constant
volts) and transferred onto nitrocellulose for 2 h at 200 mA. The nitrocellulose
was stained with Ponceau S for 10 min to monitor loading of the wells. After an
overnight incubation in blocking solution (0.5% Tween 20 in phosphate-buffered
saline [PBS]), four nitrocellulose membranes with the same bacterial antigens
were concurrently processed and developed with the following antisera for 1 h at
room temperature: anti-nHgbAI 1 (1), anti-nHgbAI 2 (current study), anti-
recombinant HgbAI (rHgbAI) (28), all at 1:25,000, and anti-rD15 at 1:10,000
(42). After three 10-min washes with 0.05% Tween 20–PBS, blots were incubated
with an alkaline-phosphatase (AP)-conjugated anti-pig or anti-rabbit secondary
Ab for 1 h at room temperature. Blots were washed 3 more times before
development with the AP chemiluminescence substrate Lumi-Phos WB (Thermo
Scientific, Rockford, IL).
Immunoprecipitation. H. ducreyi strains were grown overnight under heme-
limiting conditions to induce maximal expression of HgbA (11). Cultures were
centrifuged and pellets resuspended in GCB to an optical density at 600 nm
(OD600) of 1.0 (approximately 5  108 CFU/ml). Ten microliters of serum was
added to 1 ml of the bacterial suspension in a microcentrifuge tube and rocked
at room temperature for 20 min. To remove unbound antibody and serum
components, the suspension was centrifuged for 1 min at 14,000 rpm, the super-
natant discarded, and the cell pellet washed with 1 ml GCB. The cell pellet was
resuspended in 100 l PBS, and 1 ml of 2% Zwittergent 3,14 (ZW 3,14) in TEN
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buffer (50 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, pH 8.0) was added to
solubilize proteins. After incubation at 37°C with agitation for 1 h, the tube was
centrifuged for 10 min at 14,000 rpm to remove insoluble debris. The superna-
tant (1.0 ml), containing ZW 3,14-soluble proteins and Ab complexes, was moved
to a new tube containing 25 l of a 50% slurry of protein A/G-agarose beads
(ExAlpha Biologicals, Shirley, MA). The tubes were incubated for 2 h to allow
binding of Ab (and their respective bound cognate antigens) to protein A/G,
centrifuged, and then washed thrice using 0.5% ZW 3,14 in TEN. The agarose
pellet was resuspended in 1.0 ml TEN and moved to a fresh tube and centrifuged,
and the supernatant was discarded. Forty microliters of 1 Laemmli sample
buffer lacking any reducing agents was added to the washed agarose, the tubes
were boiled for 5 min at 95°C, and 15 l was subjected to a 4-to-12% gradient
SDS-PAGE gel and rapid Coomassie blue staining (20-min soak in 37 ml of
0.114% [wt/vol] Coomassie blue R-250 plus 20 ml of 0.0214% [wt/vol] Bismark
Brown in 40% methanol, 7% acetic acid).
Hb blocking assays. The ability of anti-nHgbAI to block binding of digoxige-
nin-labeled Hb (DIG-Hb) to nHgbAI was measured using two methods: an
Hb-blocking ELISA, as previously described (13), and a whole-cell blocking
ELISA. For both methods, 1 mg of bovine Hb (Sigma-Aldrich, St. Louis, MO)
was labeled with DIG following the manufacturer’s instructions (Roche Diag-
nostics GmbH, Germany) and frozen at 80°C. In the Hb blocking ELISA, wells
of an ELISA plate (Costar flat-bottom, high binding plate; catalog number 3590;
Cambridge, MA) were incubated overnight with 100 ng of nHgbAI before block-
ing with 2% bovine serum albumin (BSA) in PBS. Purified anti-nHgbAI IgG (20
g of IgG purified using a protein A/G resin) was then added to each well and
incubated for 30 min before addition of 400 ng of DIG-Hb in 1% BSA–PBS,
allowing the incubation to continue for an additional hour. Wells were washed 3
times with 0.05% Tween 20–PBS, and then AP-conjugated anti-DIG (1:5,000;
Roche Diagnostics, Indianapolis, IN) was added to each well and incubated for
1 h. After 3 more washes, the One-Step PNPP substrate (Pierce, Rockford, IL)
was added to the wells, the plate incubated for 45 min, and optical density was
measured at 405 nm by using the 1420 Victor2 multilabel reader (Perkin-Elmer,
MA).
For the whole-cell Hb blocking assay, 1-ml aliquots of suspensions at an OD600
of 0.5 of H. ducreyi strains 35000HPhgbAI and 35000HPhgbA (negative con-
trol), grown in low-heme GCB, were mixed with 50, 100, or 250 g of anti-
nHgbAI IgG (purified using protein A/G) for 30 min at room temperature.
DIG-Hb (200 ng) was then added to the bacteria/IgG suspensions and incubated
for another 30 min at room temperature. The cells were subsequently washed 3
times with GCB, moved to a new microcentrifuge tube, and washed one more
time in GCB. The bacterial cell pellets were suspended in Laemmli sample buffer
containing -mercaptoethanol and subjected to SDS-PAGE (4-to-12% gradient
gel) and Western blotting (1 h at 200 mA) with an AP-conjugated anti-DIG Ab
(1:500; 2 h at room temperature; Roche Diagnostics, Germany). Blots were
developed using an AP chemiluminescent substrate as described above.
Infection and processing of biopsy specimens. Twenty-four hours after infu-
sion of the pooled nHgbAI antiserum or the NPS, ears of passively immunized
animals were infected with H. ducreyi strains 35000HPhgbAI and 35000HPhgbAII
by using multitest skin test applicators (Lincoln Diagnostics, Decatur, IL) as
previously described (1, 13). Inocula were prepared by scraping H. ducreyi grown
on CAPs (grown for 15 h at 34.5°C in 5% CO2) in GCB (OD600, 1.5; approxi-
mately 1  109 CFU/ml). Prior to inoculation, the ears of the animals were
thoroughly washed with isopropyl alcohol-soaked wipes. The left ear of each
animal was inoculated in separate sites with strain 35000HPhgbAI at 104 CFU (10
l of a 109-CFU/ml inoculum; [1.06  0.19]  104 CFU [mean  standard
deviation]) or 103 CFU (10 l of a 108-CFU/ml inoculum; [0.924  0.17]  103
CFU). The right ear was similarly infected with approximately 104 or 103 CFU of
35000HPhgbAII ([1.11  0.2]  104 CFU and [1.03  0.34]  103 CFU, respec-
tively). Seven days after infection, six 6-mm biopsy punches of the lesion sites
were removed from each ear and processed for culture and histology. Four
biopsy specimens for each strain and inoculum size were minced with a sterile
scalpel and incubated for up to 72 h on CAPs supplemented with 1% GGC, 5%
FetalPlex, and 3 g/ml vancomycin at 34.5°C in 5% CO2. Cultures of H. ducreyi
were confirmed by colony characteristics (color, morphology, and cohesiveness)
and PCR using primers specific for hgbAI and hgbAII (13). The remaining 2
biopsy specimens were incubated in 4% paraformaldehyde prior to hematoxylin
and eosin (H&E) staining and processing at the Histology Laboratory of the
College of Veterinary Medicine at NCSU. A Leica DM IRB inverted microscope
(Leica Microsystems, Bannockburn, IL) was used to view the slides, and images
were saved using Q capture software (Q-Imaging, Surrey, BC, Canada). Slides
were graded independently by two persons using the previously described histo-
logic scale (1, 13, 35). Cohen’s kappa statistic for the two raters (  0.544)
indicated moderate agreement.
Statistics. Statistical analyses were performed using Sigma Stat (version 3.5;
Systat Software, Chicago, IL).
RESULTS
Passive immunization with anti-nHgbAI protected pigs from
a homologous challenge. Two parameters were used to deter-
mine if passive immunization with anti-nHgbAI protected
against a challenge: tissue damage and bacterial recovery. Tis-
sue damage was measured by determining the severity of the
lesions at the macroscopic and microscopic levels. Macroscopic
examination of the sites infected with the homologous strain
35000HPhgbAI in animals passively immunized with anti-
nHgbAI revealed a few small, pink lesions, and in most cases,
no lesion was visible, except for markings left by the applicator
device (Fig. 1A, panel 1, left ear). Conversely, lesions resulting
from infection with the heterologous strain 35000HPhgbAII, an
isogenic strain of H. ducreyi 35000HP that differs only in the
expression of the heterologous HgbAII instead of HgbAI, were
larger, raised, red, and inflamed (Fig. 1A, panel 1, right ear),
similar to sites that developed in animals passively immunized
with NPS after infection with either 35000HPhgbAI or
35000HPhgbAII (Fig. 1A, panel 2).
Microscopic analysis of H&E-stained biopsy specimens was
consistent with macroscopic observations. Sites infected with
strain 35000HPhgbAI in animals passively immunized with
anti-nHgbAI showed a low-level inflammatory infiltrate, and
the dermis, epidermis, and basement membranes were intact
(Fig. 1B, panel 3). Conversely, biopsy specimens from NPS-
immunized animals infected with the homologous strain
showed destruction of the dermis and epidermis and a massive
inflammatory infiltrate (Fig. 1B, panel 5). A large influx of
inflammatory cells and tissue destruction was also the hallmark
of sites infected with the heterologous strain, regardless of the
antiserum used to passively immunize the animals (Fig. 1B,
panels 4 and 6). H&E-stained biopsy sections were graded
using the 1 to 5 grading system previously described (1, 13).
Briefly, a score of 1 was assigned to healthy skin, while 5
characterized a fully developed ulcerative lesion. Animals pas-
sively immunized with anti-nHgbAI and infected with the ho-
mologous strain had a mean lesion grade of 1.81  1.1, com-
pared to 4.42  0.74 in animals infused with NPS (P 	 0.001,
t test). Conversely, there was not a statistically significant dif-
ference between the mean lesion grades of sites infected with
the heterologous strain in nHgbAI antisera-infused animals
(4.1  1.1) and animals that received NPS (3.75  1; P 
0.567, t test).
Bacterial recovery was determined by culturing lesions taken
from animals immunized with either anti-nHgbAI or NPS. At
the lower inoculum dose (103 CFU), animals that received the
nHgbAI antiserum were completely protected from a homol-
ogous challenge; we were unable to recover viable H. ducreyi
from any of the 16 sites biopsied from 4 pigs (Table 1), com-
pared to recovery of viable bacteria from all 12 sites in 3 pigs
that received NPS (P 	 0.001, Fisher’s exact test). At the
higher inoculum dose (104 CFU), viable homologous H. du-
creyi organisms were recovered from 3 out of 16 sites biopsied
from the 4 animals immunized with the nHgbAI antiserum
(Table 1), compared to culture from all 12 lesions recovered in
the 3 NPS-immunized animals (P 	 0.001). H. ducreyi
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35000HPhgbAII expressing the heterologous HgbA protein was
recovered from all sites on all animals, regardless of their
immunization or the inoculum size (Table 1). Thus, there was
complete protection from homologous infection at the lower
challenge dose but no protection from a heterologous chal-
lenge was observed.
Potential mechanisms of protection of anti-nHgbAI. There
are several mechanisms that may account for the protection ob-
served in this passive immunization trial with anti-nHgbAI. From
active immunization trials (1, 13), correlates of protection of the
nHgbAI vaccine included cell surface binding as well as bacteri-
cidal activity and blocking of Hb binding; there was no indication
that opsonophagocytosis was involved in the mechanism of pro-
tection of the HgbA vaccine (1). Sera from individual animals
actively immunized with nHgbAI, the antisera used for passive
transfer, as well as sera from passively immunized animals were
therefore tested for reactivity to nHgbAI, binding to viable H.
ducreyi, and bactericidal and Hb blocking activities.
Anti-nHgbAI binds purified nHgbAI. The reactivities of in-
dividual and pooled antisera to nHgbAI were first tested in a
FIG. 1. Macroscopic (A) and microscopic (B) examination of experimental H. ducreyi lesions from passively immunized pigs. Anti-
nHgbAI (top) or NPS (bottom) was passively transferred to naïve pigs 24 h prior to a challenge with homologous (35000HPhgbAI) or
heterologous (35000HPhgbAII) H. ducreyi strains. (A) Representative photographs of pig ears challenged with either H. ducreyi strain
35000HPhgbAI (left ear) or 35000HPhgbAII (right ear). Photos were taken 7 days after an infectious challenge with the designated strains
and immediately before biopsy specimens were harvested. (B) Representative H&E-stained biopsy specimens of lesions from passively
immunized animals challenged with either H. ducreyi strain 35000HPhgbAI (panels 3 and 5) or 35000HPhgbAII (panels 4 and 6). Magnifi-
cation, 50.
TABLE 1. Recovery of H. ducreyi from immunized pigsa
Challenge strain Expt no.
NPS immunization Anti-nHgbAI immunization
Pig
H. ducreyi-positive biopsies (% of 4
total biopsies) after inoculation with: Pig
H. ducreyi-positive biopsies (% of
4 total biopsies) after
inoculation with:
103 CFU 104 CFU 103 CFU 104 CFU
Class I strain, 1 C 0 0
35000HPhgbAI B 4 (100) 4 (100) D 0 0
2 E 4 (100) 4 (100) G 0 2 (50)
F 4 (100) 4 (100) H 0 1 (25)
Total 12 (100) (A) 12 (100) (B) 0 (0) (A) 3 (19) (B)
Class II strain, 1 C 4 (100) 1 (25)
35000HPhgbAII B 4 (100) 4 (100) D 4 (100) 4 (100)
2 E 4 (100) 4 (100) G 4 (100) 4 (100)
F 4 (100) 4 (100) H 4 (100) 4 (100)
Total 12 (100) 12 (100) 16 (100) 13 (81)
a Results followed by the same uppercase letter were significantly different: A and B, P 	 0.001.
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direct ELISA with purified nHgbAI. As shown in Fig. 2, sera
from each of the 4 animals actively immunized with nHgbAI
(Fig. 2, left, numbers 1 through 4), as well as the pooled sera
delivered in both passive immunization experiments (Fig. 2,
pool), were highly reactive to purified nHgbAI. Sera obtained
from swine 24 h after passive immunization with the nHgbAI
antisera (Fig. 2, bars C, D, G, and H) also showed reactivity to
nHgbAI, albeit at lower levels than sera from animals actively
immunized with nHgbAI. Based on the relative size of the
animals and the assumption that pigs have a mean blood vol-
ume of 62.5 ml per kg of weight (see Materials and Methods
for more details), the dilution of the antisera was about 1/20 to
1/30 (3 to 5% of blood volume). Pooled antisera from naïve
pigs (NPS pool) did not react to purified nHgbAI (Fig. 2).
The amount of nHgbAI-specific Abs present in the antisera
of passively immunized animals was also measured using an
indirect ELISA. The concentrations of nHgbAI-specific Abs in
antisera from pigs C and D were 0.233  0.05 and 0.277 
0.055 mg/ml, respectively. In sera from pigs G and H, the
concentration of anti-nHgbAI-specific Abs was 0.177  0.025
and 0.183  0.045 mg/ml, respectively.
Anti-nHgbAI 2 exhibited cross-reactivity to H. ducreyi strain
35000HPhgbA in a whole-cell binding ELISA. To avoid con-
fusion between antisera produced using Freund’s adjuvant,
antisera from the study published in 2006 (1) were designated
anti-nHgbAI 1 and the antisera from the present study were
designated anti-nHgbAI 2. nHgbAI antisera 1 was used in the
various in vitro assays as a positive control.
In both active immunization trials with the HgbA vaccine,
using either Freund’s or MPL adjuvants, reactivities of the
antisera to HgbA at the surface of H. ducreyi correlated with
protection (1, 13). To determine if nHgbAI antisera 2 bound
HgbA at the surface of intact, viable H. ducreyi cells, individual
and pooled nHgbAI antisera were subjected to a whole-cell
binding ELISA. Reactivities of these different antisera to H.
ducreyi strains 35000HPhgbAI, 35000HPhgbAII, and DMC111
were compared to the reactivity of the antisera to the isogenic
hgbA mutant 35000HPhgbA. There was high reactivity of
all individual and pooled anti-nHgbAI 2 to H. ducreyi
strain 35000HPhgbAI (Fig. 3A, right, and B, pool, black
bars). However, anti-nHgbAI 2 also exhibited high reactiv-
ities to strains 35000HPhgbA, 35000HPhgbAII, and DMC111
(Fig. 3A, right), which was not present in anti-nHgbAI 1 (Fig.
3A, left).
To identify the antigen(s) targeted by the cross-reactive
anti-nHgbAI 2, Western blot assays were performed using
total cellular protein from H. ducreyi strains 35000HPhgbAI,
35000HPhgbA, 35000HPhgbAII, DMC111, and a panel of iso-
genic H. ducreyi mutants grown in low-heme GCB. Anti-
nHgbAI 1 showed little reactivity to any denatured bacterial
component, including HgbA, in a Western blotting format
(Fig. 4A), as previously described (1); however, anti-nHgbAI 2
reacted with denatured HgbA (Fig. 4B). Anti-nHgbAI 2 also
showed minor reactivity to the major outer membrane pro-
teins MOMP and OmpA2 (range, 31 to 45 kDa) (16). We
were able to identify these bands as MOMP and OmpA2, as
they were absent in the lanes containing isogenic mutants
35000HPmomp and 35000HPompA (Fig. 4B).
Anti-nHgbAI 2 binds HgbA at the surface of H. ducreyi as
measured in an immunoprecipitation assay. To ensure that
anti-nHgbAI 2 bound HgbA in a native conformation in the
context of whole H. ducreyi cells and to identify putative targets
of the cross-reactivity displayed in the whole-cell binding
ELISA with these pooled antisera, anti-nHgbAI 1 and 2 pools
as well as control antisera were subjected to an immunopre-
cipitation assay (Fig. 5). Anti-nHgbAI 2 precipitated only
HgbA from H. ducreyi strain 35000HPhgbAI grown in a low-
heme culture. To confirm that this band was HgbA, these same
immunoprecipitation samples were subjected to a Western
blot assay using a rabbit polyclonal anti-rHgbAI antibody (28).
The anti-rHgbAI Ab recognized a band only in those lanes
where an HgbA band appeared in the Coomassie-stained gel
(data not shown). Conversely, control lanes loaded with mate-
rial from an immunoprecipitation assay using only protein A-
agarose or agarose and IgG yielded either no band or bands
that comigrated with the bands labeled IgG, respectively, in a
Coomassie-stained SDS-PAGE gel (data not shown). Neither
antiserum precipitated nHgbAII from strain 35000HPhgbAII,
but both did so at a low level in strain DMC111. Pooled
antiserum from naïve pigs (NPS) did not precipitate any pro-
tein from any of the tested strains.
Anti-nHgbAI 2 partially blocks binding of DIG-Hb to HgbA.
Based on the data from the whole-cell ELISA and immuno-
precipitation assays (Fig. 3 and 5, respectively) and the fact
that anti-nHgbAI 2 protected against a homologous challenge
(Fig. 1), this second preparation of nHgbAI antiserum appears
to bind HgbA in its native conformation. We therefore studied
the biological activities of this antiserum, including bactericidal
activity and its capacity to block Hb binding to HgbA. No
bactericidal activity was detected in any nHgbAI antisera (data
not shown). However, both pools of anti-nHgbAI 2, as well as
IgG purified from these antisera, partially blocked binding of
DIG-Hb to purified nHgbAI in an ELISA-type assay (Fig. 6A).
FIG. 2. Reactivity of anti-nHgbAI Abs to purified nHgbAI. The
activity of the nHgbAI/Freund’s antisera was measured using an
ELISA with nHgbAI as coating antigen. Data are expressed as OD405
readings, shown as means  standard deviations obtained from at least
3 separate experiments. The 4 left bars indicate the reactivity of the
antiserum from each donor pig actively immunized with nHgbAI.
The middle section of the graph (Exp. 1 and 2) shows the reactivity of
the pooled antisera for each passive immunization experiment (pool)
and that of the antiserum from each animal after infusion with the
pooled nHgbAI antiserum (C, D, G, and H). The right side of the
graph shows the reactivity of NPS to purified nHgbAI. Antisera were
diluted 1:5,000.
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This activity was observed in ranges similar to that obtained
with anti-nHgbAI 1 (69% inhibition compared to 64 to 66%
inhibition for anti-nHgbAI 2). Anti-nHgbAI 2 and IgG blocked
DIG-Hb binding to HgbA significantly better than NPS or
irrelevant anti-rDsrA antisera and IgG (Fig. 6A).
To determine whether anti-nHgbAI 2 could block Hb bind-
ing in the context of viable bacteria, we developed a whole-cell
Hb blocking assay. As shown in Fig. 6B, addition of 50, 100, or
250 g of anti-nHgbAI IgG significantly reduced the density of
the Hb band on the Western blot by 15, 20, and 39%, respec-
tively (P  0.026 for 50 g, P  0.004 for 100 g, and P 	 0.001
for 250 g of anti-nHgbAI 2 IgG; Mann-Whitney rank sum
test), consistent with the ability of the antisera to block Hb
binding to purified nHgbAI in the ELISA (Fig. 6A, 47 and 49%
reduction for anti-nHgbAI 2 IgG experiments 1 and 2, respec-
tively). In contrast, 250 g of anti-nHgbAI 2 IgG did not
significantly reduce binding of DIG-Hb to H. ducreyi strains
35000HPhgbAII and DMC111 (4% reduction in band density,
compared to results with no addition of anti-nHgbAI IgG),
which express a class II HgbA protein on the bacterial surface.
DISCUSSION
Passive immunization with antisera elicited by the HgbAI
vaccine protects against a homologous H. ducreyi challenge in
the experimental swine model of chancroid. Previous reports
from our laboratory showed that a native preparation of HgbA,
the Hb receptor of H. ducreyi, is a successful vaccine in the
FIG. 3. Whole-cell binding of anti-nHgbAI Abs. (A) The reactivities of the Abs from individual pigs actively immunized with nHgbAI (pigs 1
to 4; anti-nHgbAI 2) to 4 different H. ducreyi strains (see the legend for Fig. 3B) were tested in a whole-cell binding ELISA. Antisera from the
first nHgbAI/Freund’s vaccine trial (anti-nHgbAI 1, pigs 6 to 8) were used positive controls. (B) Pooled nHgbAI antisera used for infusion in each
passive immunization experiment and antisera from passively immunized animals (animals C, D, G, and H) were tested in a whole-cell binding
assay using the same H. ducreyi strains as shown in Fig. 3A. Pool, anti-nHgbAI 2 pool; NPSp, normal pig serum pool.
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experimental swine model of chancroid (1, 13). Whether
nHgbA is administered with Freund’s adjuvant or MPL, an ad-
juvant currently used in humans, the antisera elicited to the
HgbA vaccine bound the surface of H. ducreyi and partially
blocked Hb binding to HgbA. These data suggested that pro-
tection by the HgbA vaccine is Ab mediated. To test this
hypothesis, we sought to determine if passive immunization of
naïve swine with nHgbAI antiserum could protect against an
infectious challenge with homologous and heterologous H. du-
creyi strains. Infusion of pigs with anti-nHgbAI prevented in-
fection with the homologous H. ducreyi strain 35000HPhgbAI
at an inoculum of 103 CFU. Thus, the humoral immune re-
sponse elicited to the nHgbA vaccine protects against an in-
fectious H. ducreyi challenge.
There was breakthrough infection at the higher inoculum
dose (104 CFU) in 2 of 4 passively immunized animals. This
may have been related to the concentration of nHgbAI-specific
Abs present in the sera of infused pigs. Although the small
sample size precluded a statistical analysis of correlations be-
tween antibody levels and passive protection, pigs with higher
levels of nHgbAI-specific Abs were completely protected from
challenge with either inoculum, while those with lower concen-
trations experienced breakthrough infections. These data sug-
gest that the amount of nHgbAI-specific Abs is important for
clearance of H. ducreyi in this animal model.
Anti-nHgbAI 2 displays the same in vitro correlates of pro-
tection as the ones identified in antisera from animals pro-
tected against a homologous H. ducreyi challenge. In 2 previous
active immunization trials using nHgbA as a vaccine, antisera
from nHgbA-vaccinated animals were tested for the ability to
bind purified nHgbA and HgbA in the context of whole H.
ducreyi, the ability to inhibit Hb binding to HgbA, and bac-
tericidal and opsonophagocytic activities. In the first vaccina-
tion trial in which the nHgbA vaccine was administered with
Freund’s adjuvant (anti-nHgbAI 1), the antisera from vacci-
nated animals bound purified nHgbA and HgbA at the surface
of H. ducreyi, had modest bactericidal activity, and partially
blocked DIG-Hb binding to nHgbAI, but lacked opsonophago-
cytic activity (1). In the second active immunization trial using
MPL as the adjuvant, the antisera from animals immunized
with nHgbAI/MPL bound nHgbAI purified from H. ducreyi and
HgbA in its native conformation, but with much less reactivity
than anti-nHgbAI 1. Nevertheless, anti-nHgbAI/MPL blocked
Hb binding to nHgbA in an ELISA to levels similar to that of
the nHgbAI/Freund’s 1 antisera, but lacked bactericidal activ-
ity. Furthermore, the nHgbA vaccine administered with MPL
FIG. 4. Reactivities of anti-HgbAI Abs to total cellular proteins
from a panel of H. ducreyi strains. The reactivities of pooled anti-
nHgbAI 2 to total cellular proteins from H. ducreyi wild-type strains
35000HPhgbAI and DMC111 and several mutants in the 35000HP
background were determined in Western blot assays. Anti-nHgbAI 1,
pooled swine polyclonal nHgbAI antiserum from a previous nHgbA
vaccine trial (pool of antisera from pigs 6, 7, and 8) (1); anti-nHgbAI
2, pooled swine polyclonal nHgbAI antiserum from the current nHgbA
vaccine trial (pool of antisera from pigs 1, 2, 3, and 4); anti-rHgbAI,
rabbit polyclonal antiserum to denatured rHgbA (28); anti-rD15, rab-
bit polyclonal antiserum to denatured rD15 (42). The Western blot
with anti-rD15 shows equal loading.
FIG. 5. Anti-nHgbAI Abs bind to the surface of H. ducreyi. The
abilities of pooled nHgbAI antisera to bind HgbA at the surface of H.
ducreyi strains 35000HPhgbAI, 35000HPhgbAI, and DMC111 were
measured in an immunoprecipitation assay. Material obtained from
the immunoprecipitation assay was subjected to a 4 to 12% SDS-
PAGE and rapid Coomassie blue staining. Pooled antisera used in this
assay were obtained from animals immunized 3 times with nHgbAI in
Freund’s adjuvant, either from a previous study (anti-nHgbAI 1) (1) or
obtained in the course of the current study (anti-nHgbAI 2). nHgbAI
STD and nHgbAII STD, 0.5 g of purified nHgbAI or nHgbAII, re-
spectively; TCP, total cellular protein from 1  107 CFU; NPSp,
normal pig serum pool. Shown is a representative gel from at least 4
different experiments with similar results.
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was protective (13). Therefore, analysis of the humoral im-
mune response developed to the HgbA vaccine from previous
studies demonstrates that binding of anti-HgbA to HgbA in its
native conformation as well as blocking of Hb binding appear to
correlate with protection (1, 13). Because there was only modest
in vitro bactericidal activity demonstrated by the nHgbAI antisera
in the first trial, and none in the second, bactericidal activity does
not appear to be necessary for protection.
The same in vitro assays described above were therefore
used to assess the biological properties of individual and
pooled anti-nHgbAI 2 used for the passive immunization ex-
periments described here. These antisera bound purified
nHgbAI and HgbAI on the surface of H. ducreyi and partially
blocked Hb binding to HgbA, again at levels similar to those
observed for anti-nHgbAI 1 (Fig. 2, 5, and 6, respectively).
However, there were some differences between the activities of
anti-nHgbAI 2 and 1. First, there was higher cross-reactivity to
the surface of the isogenic hgbA mutant strain 35000HPhgbA
by anti-nHgbAI 2. From Western blot assays, the anti-nHgbAI
2 bound denatured HgbA more than anti-nHgbAI 1 (Fig. 4A
and B). Potential explanations for these differences include
modification of the protein structure during preparation of the
individual vaccines and genetic differences between swine
herds; the animals used to generate anti-nHgbAI 2 came from
a different farm and are likely distantly related to the animals
that were previously used to conduct the HgbA vaccination
trials. Anti-nHgbAI 2 also contained Abs that recognized the
two major outer membrane proteins of H. ducreyi, MOMP and
OmpA2 (Fig. 4B). There are a number of proteins from pig
pathogens that have high homology to the major outer mem-
brane proteins of H. ducreyi (23). Because these pathogens are
early colonizers and infection by these pathogens is often en-
demic and mostly asymptomatic (P. Routh, personal commu-
nication), it is possible that one or more of the animals immu-
nized with nHgbAI/Freund’s vaccine may have been colonized
with such cross-reacting bacteria. This would have contributed
to the reactivity of the pooled anti-nHgbAI 2 to H. ducreyi
MOMP and OmpA2. Western blot analysis of the nHgbAI
preparation used to generate anti-nHgbAI 2 with monoclonal
antibody 2C7, which recognizes both MOMP and OmpA2
(37), revealed that MOMP and/or OmpA2 was present in the
preparations; however, the amount was undetectable by Coo-
massie blue staining or silver staining (data not shown).
Antisera elicited to nHgbAI only protect against a homolo-
gous challenge. H. ducreyi strains are grouped into classes,
termed class I and class II, according to the expression of
variant outer membrane determinants and the structure of
LOS (33, 34, 36, 48). Although the amino acid sequences
of some H. ducreyi surface determinants, such as DsrA and
NcaA, differ widely between H. ducreyi strains belonging to
different classes, the HgbA protein is highly conserved, with
more than 95% identity between HgbA proteins in the two
strain classes (26, 48). Most of these differences reside in the
large immunodominant loop 4 of HgbA, which contains 17
different putatively surface-exposed amino acids out of a total
of only 27 different residues between full-length HgbA proteins
of different classes (950 total amino acids) (26). Because of this
high identity between HgbA proteins of different groups, we
were surprised to discover that the nHgbAI vaccine did not
protect against infection with H. ducreyi strain 35000HP ex-
pressing class II HgbA (13). The current data from passive
immunization are consistent with these previous results.
Pooled antisera elicited to the HgbAI vaccine were only pro-
tective against infection with an H. ducreyi strain expressing
HgbAI. Taken together, these data suggest that differences in
a small number of immunogenic, variable residues in HgbAI
FIG. 6. Anti-nHgbAI Abs partially block Hb binding by HgbA.
(A) The abilities of pooled nHgbAI antisera or purified IgG to block
binding of DIG-Hb to nHgbAI were measured using an Hb blocking
ELISA. The anti-nHgbAI 1 pool from a previous study was used as a
positive control (1), while the irrelevant polyclonal antisera to the
outer membrane trimeric autotransporter DsrA (anti-rDsrA) was used
as a negative control (48). Results are expressed as the percentage of
a no-antibody control, arbitrarily defined as 0% inhibition of DIG-Hb
binding to nHgbA. Data were compared using a Mann-Whitney rank
sum test. NPSp, normal pig serum pool. (B) The abilities of anti-
nHgbAI 2 IgG to block binding of DIG-Hb to H. ducreyi strains
35000HPhgbAI, 35000HPhgbAII, and DMC111 were analyzed using a
whole-cell Hb blocking assay. Bands on the Western blot were ana-
lyzed with NIH Image (version 1.62) and are arbitrarily expressed as
the percent reduction in band density compared to the strain plus
DIG-Hb without the addition of IgG (indicated as 0). Bold numbers
indicate a statistically significant reduction in band density (Mann-
Whitney rank sum test). The DIG-Hb lane (10 ng) served as a standard
(STD). Shown is a representative Western blot from 4 different exper-
iments with similar results.
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and HgbAII contribute to protection by an HgbA-based vac-
cine. Therefore, a bivalent HgbA vaccine may be necessary to
prevent chancroid caused by both classes of H. ducreyi strains.
Another potential explanation for the lack of heterologous
protection lies in the different exposure of the class II HgbA
protein on the surface of H. ducreyi strains 35000HP and
DMC111. The LOS of the class II strain DMC111 is truncated
(48), and this smaller LOS structure may result in greater
exposure of HgbA at the surface of class II H. ducreyi. How-
ever, because H. ducreyi class II strain DMC111 is noninfec-
tious in the experimental swine model of infection, we were
unable to examine the protective capacity of a class I antibody
response against infection with a naturally occurring class II
strain. It is therefore possible that natural class II strain infec-
tions may be protected by the class I vaccine. Further studies
are needed to clarify this issue.
A possible mechanism of protection of the HgbA vaccine is
nutritional immunity. Iron is required for the growth of most
bacteria. However, iron in the host is sequestered from invad-
ing pathogens by several different proteins (47). Kochan used
the term “nutritional immunity” to describe this process of
“depletion by the host of iron essential for bacterial growth.”
He associated this term with acquired immunity to relate it to
the limitation of an essential nutrient by the host iron/heme-
scavenging proteins (17). The idea of preventing a pathogen
from acquiring an essential nutrient is decades old; however,
this report, along with others from our laboratory (1, 13), are
the first to suggest that vaccine-induced nutritional immunity
can actually occur in the host. Our studies with the HgbA
vaccine show that antisera elicited to an Hb receptor can par-
tially prevent Hb binding to the Hb receptor itself, suggesting
that nutritional immunity is possible (Fig. 6). Further experi-
ments are under way to determine if anti-nHgbAI IgG can
prevent bacterial growth.
In conclusion, we have shown in this report that passive
immunization with pooled antisera from swine immunized with
the Hb receptor of H. ducreyi protected naïve pigs against a
homologous challenge in the experimental swine model of
chancroid. Our results also suggest that the mechanism of
protection of the HgbA vaccine may be nutritional immunity,
since Abs elicited to the H. ducreyi Hb receptor were not
bactericidal but partially prevented HgbA from binding its
ligand, Hb.
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